Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lurbinectedin - PharmaMar

Drug Profile

Lurbinectedin - PharmaMar

Alternative Names: PM-01183; PM-1183; Tryptamicidin; Zepsyre

Latest Information Update: 30 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaMar
  • Developer Fundacion Instituto Valenciano de Oncologia; PharmaMar; Swiss Group for Clinical Cancer Research
  • Class 3-ring heterocyclic compounds; Acetates; Alkaloids; Antineoplastics; Carbolines; Dioxolanes; Indoles; Small molecules; Tetrahydroisoquinolines
  • Mechanism of Action Cell cycle inhibitors; RNA polymerase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Ovarian cancer; Small cell lung cancer
  • Phase II Breast cancer; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • No development reported Leukaemia

Most Recent Events

  • 24 Jan 2019 The Committee for Orphan Medicinal Products of the EMA recommends orphan drug designation for lurbinectedin for Small cell lung cancer
  • 18 Dec 2018 PharmaMar and the Swiss Group for Clinical Cancer Research completes enrolment in a phase II trial for Mesothelioma in Switzerland
  • 19 Oct 2018 Final efficacy and adverse events data from a phase III CORAIL trial in Ovarian cancer (Second-line therapy or greater) presented at the43rd European Society for Medical Oncology Congress (ESMO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top